Clinical Trial Update: Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating optimized retreatment and prolonged therapy with bortezomib in multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Janssen-Cilag International NV | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED